Published 3 days ago • loading... • Updated 3 days ago

Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Curis, Inc., a biotechnology company listed on NASDAQ as CRIS in Lexington, Massachusetts, granted inducement stock options to Dr. Ahmed Hamdy on May 6, 2025.
The Board of Directors approved the grant to Dr. Hamdy, who was newly appointed Chief Medical Officer, as a material inducement for accepting employment.
The inducement grant, dated May 1, 2025, allows Dr. Hamdy to purchase 200,000 shares at the closing stock price of that day, vesting over four years with a 10-year term.
Emavusertib , a small molecule IRAK4 inhibitor that Curis exclusively licenses and develops, is currently under multiple Phase 1/2 trials for various blood cancers and has FDA orphan drug designations.
This inducement grant supports Curis’ leadership in advancing emavusertib’s development and suggests commitment to clinical progress in hematologic cancer therapies.

Insights by Ground AI

Does this summary seem wrong?

55 Articles

All

Left

Center

Right

The Conway Daily Sun

+54 Reposted by 54 other sources

Center

Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

LEXINGTON, Mass., May 6, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Board of Directors of Curis approved the grant…

3 days ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year